Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors
| Status: | Completed |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 99 |
| Updated: | 12/23/2018 |
| Start Date: | October 11, 2005 |
| End Date: | September 23, 2010 |
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 DOSING SCHEDULES OF PF-00299804 IN PATIENTS WITH ADVANCED MALIGNANT SOLID TUMORS
The primary purpose of this study is to study the side effects of PF-00299804 and determine
the highest dose that can be safely administered in patients with advanced cancer.
the highest dose that can be safely administered in patients with advanced cancer.
Inclusion Criteria:
- Malignant solid tumor for which there is no currently approved treatment
- Adequate bone marrow, liver, cardiac, and kidney function
Exclusion Criteria:
- Cardiac disease
- Anticancer therapy within 4-6 weeks (depending on therapy)
- Pregnant or breast-feeding
We found this trial at
9
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials